Seres Therapeutics (NASDAQ:MCRB) Cut to Sell at StockNews.com
StockNews.com cut shares of Seres Therapeutics (NASDAQ:MCRB – Free Report) from a hold rating to a sell rating in a research note issued to investors on Thursday. MCRB has been the topic of several other reports. The Goldman Sachs Group lowered their price target on Seres Therapeutics from $20.00 to $15.00 and set a “sell” […]
StockNews.com cut shares of Seres Therapeutics (NASDAQ:MCRB – Free Report) from a hold rating to a sell rating in a research note issued to investors on Thursday. MCRB has been the topic of several other reports. The Goldman Sachs Group lowered their price target on Seres Therapeutics from $20.00 to $15.00 and set a “sell” […]
